Authors : Induru Jagadeesh; M.V. Sree Hrullekha

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/3sh3fvwb

Scribd : https://tinyurl.com/ycyvta82

DOI : https://doi.org/10.38124/ijisrt/25aug911

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : The limitations of chemotherapy in toxicity and patient compliance made the targeted and stimuli responsive drug delivery as the focal point in oncological research. This article reviews the responsive drug delivery systems that leverages the pathological characteristics or conditions of tumor microenvironment [TME] such as hypoxia, acidic pH, overexpressed enzymes, high levels of reactive oxygen species [ROS] and glutathione [GSH], to specifically release the drug and increase the accumulation of the drug at tumor site and reduce the unnecessary damage to healthy cells, thus decreasing the side effects. These physiological abnormalities act as triggers to release drug at required site. These drug delivery systems incorporate pH sensitive/responsive moieties, enzyme cleavable links, redox sensitive components allowing for precise control over when and where drugs are released, thereby minimizing damage to healthy tissue and increasing therapeutic efficacy. These intelligent systems have the potential to address issues with conventional treatment, such as off-target effects, systemic toxicity, low bioavailability, and drug resistance. As research evolves these technologies are likely to play a key role in future of cancer treatment. This review also presents brief idea of the TME and its salient characteristics, explains how TME-responsive moieties enable drug release, and briefly summarizes the basic ideas of targeted and stimuli-responsive delivery.

Keywords : Tumor Microenvironment, Chemotherapy, Stimuli Responsive Drug Delivery, Targeted Drug Delivery, Ph Sensitive/Responsive Moieties, Enzyme Cleavable Links, Redox Sensitive Components.

References :

1. S.H. Hassanpour and M. Dehghani, “Review of cancer from perspective of molecular,” J. Cancer Res. Pract., vol. 4, no. 4, pp. 127–129, Dec. 2017.
2. B. Liu, H. Zhou, L. Tan, K.T.H. Siu, and X.Y. Guan, “Exploring treatment options in cancer: Tumor treatment strategies,” Signal Transduct. Target. Ther., vol. 9, no. 1, pp. 1–44, Jul. 2024.
3. D.T. Debela, S.G. Muzazu, K.D. Heraro, M.T. Ndalama, B.W. Mesele, D.C. Haile, S.K. Kitui, and T. Manyazewal, “New approaches and procedures for cancer treatment: Current perspectives,” SAGE Open Med., vol. 9, pp. 1–12, Aug. 2021. [vol. 9, Art. no. 20503121211034366, Aug. 2021.]
4. V.V. Veselov, A.E. Nosyrev, L. Jicsinszky, R.N. Alyautdin, and G. Cravotto, “Targeted delivery methods for anticancer drugs,” Cancers, vol. 14, no. 3, pp. 1–15, Jan. 2022.
5. M.A. Rahim et al., “Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting,” Cancers, vol. 13, Art. no. 670, 2021.
6. A.M. Sofias, F. Combes, S. Koschmieder, G. Storm, and T. Lammers, “A paradigm shift in cancer nanomedicine: From traditional tumor targeting to leveraging the immune system,” Drug Discov. Today, vol. 26, no. 6, pp. 1482–1489, Jun. 2021.
7. Q. He et al., “Tumor microenvironment responsive drug delivery systems,” Asian J. Pharm. Sci., vol. 15, no. 4, pp. 416–448, Jul. 2020.
8. N.M. Anderson and M.C. Simon, “The tumor microenvironment,” Curr. Biol., vol. 30, no. 16, pp. R921–R925, Aug. 2020.
9. Z. Jin, M. Al Amili, and S. Guo, “Tumor microenvironment-responsive drug delivery based on polymeric micelles for precision cancer therapy: Strategies and prospects,” Biomedicines, vol. 12, no. 2, Art. no. 417, Feb. 2024.
10. S. Peng, F. Xiao, M. Chen, and H. Gao, “Tumor microenvironment‐responsive nanomedicine for enhanced cancer immunotherapy,” Adv. Sci., vol. 9, no. 1, Art. no. 2103836, Nov. 2021.
11. S. Uthaman, K.M. Huh, and I.-K. Park, “Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications,” Biomater. Res., vol. 22, Art. no. 22, 2018.
12. M.V. Liberti and J.W. Locasale, “The Warburg effect: How does it benefit cancer cells?” Trends Biochem. Sci., vol. 41, no. 3, pp. 211–218, Mar. 2016.
13. M. Li, G. Zhao, W.K. Su, and Q. Shuai, “Enzyme-responsive nanoparticles for anti-tumor drug delivery,” Front. Chem., vol. 8, Art. no. 647, Jul. 2020.
14. E.C. Cheung and K.H. Vousden, “The role of ROS in tumour development and progression,” Nat. Rev. Cancer, vol. 22, pp. 280–297, 2022.
15. F. Weinberg, N. Ramnath, and D. Nagrath, “Reactive oxygen species in the tumor microenvironment: An overview,” Cancers, vol. 11, no. 8, Art. no. 1191, 2019.
16. C.L. Kuo et al., “Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: Foe or friend?” J. Biomed. Sci., vol. 29, Art. no. 74, 2022.
17. L. Kennedy, J.K. Sandhu, M.E. Harper, and M. Cuperlovic-Culf, “Role of glutathione in cancer: From mechanisms to therapies,” Biomolecules, vol. 10, no. 10, Art. no. 1429, Oct. 2020.
18. X. Du, Y. Gao, Q. Kang, and J. Xing, “Design and applications of tumor microenvironment-responsive nanogels as drug carriers,” Front. Bioeng. Biotechnol., vol. 9, Art. no. 771851, Oct. 2021.
19. J. George Joy, G. Sharma, and J.C. Kim, “Tailoring polymeric nanocarriers for hypoxia-specific drug release: Insights into design and applications in clinics,” Chem. Eng. J., vol. 496, Art. no. 153978, Jul. 2024.
20. Y. Xia, S. Duan, C. Han, C. Jing, Z. Xiao, and C. Li, “Hypoxia-responsive nanomaterials for tumor imaging and therapy,” Front. Oncol., vol. 12, Art. no. 1089446, Dec. 2022.
21. Y. Li, L. Zhao, and X.F. Li, “Targeting hypoxia: Hypoxia-activated prodrugs in cancer therapy,” Front. Oncol., vol. 11, Art. no. 700407, Jul. 2021.
22. H. Alimoradi, S. Matikonda, A.B. Gamble, G.I. Giles, and K. Greish, “Hypoxia responsive drug delivery systems in tumor therapy,” Curr. Pharm. Des., vol. 22, no. 19, pp. 2808–2820, May 2016.
23. N. Filipczak et al., “Hypoxia-sensitive drug delivery to tumors,” J. Control. Release, vol. 341, pp. 431–442, Jan. 2022.
24. F. Galieva, M. Khalifa, Z. Akhmetzyanova, D. Mironova, V. Burilov, S. Solovieva, and I. Antipin, “New supramolecular hypoxia-sensitive complexes based on azo-thiacalixarene,” Molecules, vol. 28, no. 2, Art. no. 466, Jan. 2023.
25. A. Sharma et al., “Hypoxia-targeted drug delivery,” Chem. Soc. Rev., vol. 48, no. 3, pp. 771–813, Feb. 201.
26. M. Zhu, G. Ren, J. Guo, X. Chen, R. Long, S. Wang, and Y. Liu, “Hypoxia-responsive nanomicelle based on 2-nitroimidazole for tumor treatment through chemotherapy and modulation of the tumor redox microenvironment,” ACS Appl. Nano Mater., vol. 7, no. 11, pp. 12452–12465, May 2024.
27. Y. Li, A. Lu, M. Long, L. Cui, Z. Chen, and L. Zhu, “Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts,” Acta Biomater., vol. 83, pp. 334–348, Jan. 2019.
28. M. Long et al., “Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery,” Acta Biomater., vol. 115, pp. 343–357, Oct. 2020.
29. M. Karimi et al., “pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents,” Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., vol. 8, no. 5, pp. 696–716, Sep. 2016.
30. H. Tang, W. Zhao, J. Yu, Y. Li, and C. Zhao, “Recent development of pH-responsive polymers for cancer nanomedicine,” Molecules, vol. 24, no. 1, Art. no. 4, 2019.
31. T. Yoshida, T.C. Lai, G.S. Kwon, and K. Sako, “pH- and ion-sensitive polymers for drug delivery,” Expert Opin. Drug Deliv., vol. 10, no. 11, pp. 1497–1513, Nov. 2013.
32. Y. Zhang, I. Kim, Y. Lu, Y. Xu, D.G. Yu, and W. Song, “Intelligent poly(L-histidine)-based nanovehicles for controlled drug delivery,” J. Control. Release, vol. 349, pp. 963–982, Aug. 2022.
33. Z. Su, T. Erdene-Ochir, T. Ganbold, and H. Baigude, “Design of curdlan-based pH-sensitive polymers with endosome buffering functionality for siRNA delivery,” Int. J. Biol. Macromol., vol. 146, pp. 773–780, Mar. 2020.
34. R.P. Johnson et al., “Poly(PEGA)-b-poly(L-lysine)-b-poly(L-histidine) hybrid vesicles for tumoral pH-triggered intracellular delivery of doxorubicin hydrochloride,” ACS Appl. Mater. Interfaces, vol. 7, no. 39, pp. 21770–21779, Oct. 2015.
35. H. Zhang et al., “pH-responsive lipid polymer hybrid nanoparticles (LPHNs) based on poly(β-amino ester) as a promising candidate to resist breast cancers,” J. Drug Deliv. Sci. Technol., vol. 61, Art. no. 102102, Sep. 2020.
36. K.H. Min et al., “Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy,” J. Control. Release, vol. 144, no. 2, pp. 259–266, Jun. 2010.
37. B. Baptista, A.S.R. Oliveira, P. Mendonça, A.C. Serra, J.F.J. Coelho, and F. Sousa, “pH-responsive nanoparticles based on POEOMA-b-PDPA block copolymers for RNA encapsulation, protection and cell delivery,” Biomater. Adv., vol. 145, Art. no. 213267, Feb. 2023.
38. R. Mo and Z. Gu, “Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery,” Mater. Today, vol. 19, no. 5, pp. 274–283, Jun. 2016.
39. S. Zhuo, F. Zhang, J. Yu, X. Zhang, G. Yang, and X. Liu, “pH-sensitive biomaterials for drug delivery,” Molecules, vol. 25, no. 23, Art. no. 5649, 2020.
40. Y. B. Long, W. X. Gu, C. Pang, J. Ma, and H. Gao, “Construction of coumarin-based cross-linked micelles with pH responsive hydrazone bond and tumor targeting moiety,” J. Mater. Chem. B, vol. 4, no. 8, pp. 1480–1488, Feb. 2016.
41. S. Chu, X. Shi, Y. Tian, and F. Gao, “pH-responsive polymer nanomaterials for tumor therapy,” Front. Oncol., vol. 12, p. 855019, Mar. 2022.
42. A. M. Jazani, N. Arezi, C. Shetty, S. H. Hong, H. Li, X. Wang, et al., “Tumor-targeting intracellular drug delivery based on dual acid/reduction-degradable nanoassemblies with ketal interface and disulfide core locations,” Polym. Chem., vol. 10, no. 22, pp. 2840–2853, 2019.
43. X. Cong, J. Chen, and R. Xu, “Recent progress in bio-responsive drug delivery systems for tumor therapy,” Front. Bioeng. Biotechnol., vol. 10, 2022.
44. Y. Wang, T. Deng, X. Liu, X. Fang, Y. Mo, N. Xie, G. Nie, B. Zhang, and X. Fan, “Smart nanoplatforms responding to the tumor microenvironment for precise drug delivery in cancer therapy,” Int. J. Nanomedicine, vol. 19, pp. 6253–6277, Jun. 2024.
45. R. de la Rica, D. Aili, and M. M. Stevens, “Enzyme-responsive nanoparticles for drug release and diagnostics,” Adv. Drug Deliv. Rev., vol. 64, no. 11, pp. 967–978, Aug. 2012.
46. J. Cathcart, A. Pulkoski-Gross, and J. Cao, “Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas,” Genes Dis., vol. 2, no. 1, pp. 26–34, Mar. 2015.
47. K. Kessenbrock, V. Plaks, and Z. Werb, “Matrix metalloproteinases: regulators of the tumor microenvironment,” Cell, vol. 141, no. 1, pp. 52–67, Apr. 2010.
48. X. Zhang, X. Wang, W. Zhong, X. Ren, X. Sha, and X. Fang, “Matrix metalloproteinases-2/9-sensitive peptide-conjugated polymer micelles for site-specific release of drugs and enhancing tumor accumulation: Preparation and in vitro and in vivo evaluation,” Int. J. Nanomedicine, vol. 11, pp. 1643–1661, Apr. 2016.
49. J. Zhang, Z. F. Yuan, Y. Wang, W. H. Chen, G. F. Luo, S. X. Cheng, R. X. Zhuo, and X. Z. Zhang, “Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery,” J. Am. Chem. Soc., vol. 135, no. 13, pp. 5068–5073, Apr. 2013.
50. Y. Li, C. Zhang, G. Li, G. Deng, H. Zhang, Y. Sun, and F. An, “Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy,” Acta Pharm. Sin. B, vol. 11, no. 8, pp. 2220–2242, Aug. 2021.
51. J. Li, F. Liu, Q. Shao, Y. Min, M. Costa, E. K. Yeow, and B. Xing, “Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells,” Adv. Healthc. Mater., vol. 3, no. 8, pp. 1230–1239, Aug. 2014.
52. L. Vecchi, T. G. Araújo, F. V. P. V. Azevedo, S. T. S. Mota, V. M. R. Ávila, M. A. Ribeiro, and L. R. Goulart, “Phospholipase A2 drives tumorigenesis and cancer aggressiveness through its interaction with Annexin A1,” Cells, vol. 10, no. 6, p. 1472, Jun. 2021.
53. S. S. Jensen, T. L. Andresen, J. Davidsen, P. Høyrup, S. D. Shnyder, M. C. Bibby, et al., “Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids,” Mol. Cancer Ther., vol. 3, no. 11, pp. 1451–1458, Nov. 2004.
54. G. Saravanakumar, J. Kim, and W. J. Kim, “Reactive-oxygen-species-responsive drug delivery systems: Promises and challenges,” Adv. Sci., vol. 4, no. 1, p. 1600124, Jun. 2016.
55. W. Tao and Z. He, “ROS-responsive drug delivery systems for biomedical applications,” Asian J. Pharm. Sci., vol. 13, no. 2, pp. 101–112, Mar. 2018.
56. J. Liu, B. Jia, Z. Li, and W. Li, “Reactive oxygen species-responsive polymer drug delivery systems,” Front. Bioeng. Biotechnol., vol. 11, Feb. 2023.
57. J. Liang and B. Liu, “ROS-responsive drug delivery systems,” Bioeng. Transl. Med., vol. 1, no. 3, pp. 239–251, Jul. 2016.
58. L. Žid, V. Zeleňák, V. Girman, J. Bednarčík, A. Zeleňáková, J. Szűcsová, et al., “Doxorubicin as cargo in a redox-responsive drug delivery system capped with water dispersible ZnS nanoparticles,” RSC Adv., vol. 10, no. 27, pp. 15825–15835, 2020.
59. N. Oddone, F. Boury, E. Garcion, A. M. Grabrucker, M. C. Martinez, F. Da Ros, A. Janaszewska, F. Forni, M. A. Vandelli, G. Tosi, B. Ruozi, and J. T. Duskey, “Synthesis, characterization, and in vitro studies of a reactive oxygen species (ROS)-responsive methoxy polyethylene glycol-thioketal-melphalan prodrug for glioblastoma treatment,” Front. Pharmacol., vol. 11, p. 574, May 2020.
60. X. Xu, P. E. Saw, W. Tao, Y. Li, X. Ji, S. Bhasin, Y. Liu, D. Ayyash, J. Rasmussen, M. Huo, J. Shi, and O. C. Farokhzad, “ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy,” Adv. Mater., vol. 29, no. 33, 2017.
61. H. F. Abed, W. H. Abuwatfa, and G. A. Husseini, “Redox-responsive drug delivery systems: A chemical perspective,” Nanomaterials, vol. 12, no. 18, p. 3183, Sep. 2022.
62. A. Raza, U. Hayat, T. Rasheed, M. Bilal, and H. M. N. Iqbal, “Redox-responsive nano-carriers as tumor-targeted drug delivery systems,” Eur. J. Med. Chem., vol. 157, pp. 705–715, Sep. 2018.
63. B. Chen, W. Dai, B. He, H. Zhang, X. Wang, Y. Wang, and Q. Zhang, “Current multistage drug delivery systems based on the tumor microenvironment,” Theranostics, vol. 7, no. 3, pp. 538–558, Jan. 2017.
64. P. Monteiro, A. Travanut, C. Conte, and C. Alexander, “Reduction-responsive polymers for drug delivery in cancer therapy—Is there anything new to discover?” WIREs Nanomed. Nanobiotechnol., vol. 13, no. 2, 2020.
65. Y. Li, K. Xiao, J. Luo, W. Xiao, J. S. Lee, A. M. Gonik, J. Kato, T. A. Dong, and K. S. Lam, “Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery,” Biomaterials, vol. 32, no. 27, pp. 6633–6645, Sep. 2011.
66. X. Guo, Y. Cheng, X. Zhao, Y. Luo, J. Chen, and W. E. Yuan, “Advances in redox-responsive drug delivery systems of tumor microenvironment,” J. Nanobiotechnol., vol. 16, no. 1, p. 74, Sep. 2018.
67. Z. Shi, J. Liu, L. Tian, J. Li, Y. Gao, Y. Xing, et al., “Insights into stimuli-responsive diselenide bonds utilized in drug delivery systems for cancer therapy,” Biomed. Pharmacother., vol. 155, p. 113707, Nov. 2022.
68. C. Fu, R. Wei, P. Xu, S. Luo, C. Zhang, R. K. Kankala, et al., “Supercritical fluid-assisted fabrication of diselenide-bridged polymeric composites for improved indocyanine green-guided photodynamic therapy,” Chem. Eng. J., vol. 407, p. 127108, Sep. 2020.